De-Coupling Process Development from Manufacturing: Turning the Traditional CDMO Model on its Head

Show Image Description

For both medicine developers and the patients they serve, the ability to innovate, scale, and efficiently bring medicines to market is critical. For decades, the pharmaceutical industry has relied on the traditional Contract Development and Manufacturing Organization (CDMO) model to handle the complexities of both process development and manufacturing. While this model has been integral to the industry's growth, it often leaves medicine developers tethered to manufacturing constraints, limiting flexibility, innovation, and control over the process.

However, a paradigm shift is underway—one that decouples process development from manufacturing, fundamentally changing how biopharma companies approach Chemistry, Manufacturing & Control (CMC) (learn more). This approach prioritizes a deep scientific understanding of processes and gives medicine developers full ownership of the data and insights required for flexible, efficient, and resilient manufacturing.

The result? Enhanced control, lower risks, and faster pathways to market.

The Limitations of the Traditional CDMO Model

The conventional CDMO model is built around the idea that both process development and manufacturing should happen under one roof. While this offers certain logistical advantages, it also imposes significant limitations:

• Process Constraints: CDMOs are often driven by the need to maximize the use of their manufacturing infrastructure. This can lead to a "one-size-fits-all" approach, where the process is forced to fit the available reactors and equipment rather than being tailored to the unique needs of the medicine. This misalignment between process development and manufacturing infrastructure can result in inefficient processes, costly delays, and even batch failures.

• Limited Innovation: In a model where manufacturing takes precedence, process development frequently becomes an afterthought. CDMOs, focused on filling production slots, may lack the deep scientific expertise or motivation to explore novel processes that could optimize scalability, efficiency, or cost. The lack of innovation in process design can stifle the potential of breakthrough therapies, compromising quality and limiting the ability to respond to changing market and regulatory demands.

• Risk of Regulatory Setbacks: Poor process understanding is one of the leading causes of Complete Response Letters (CRLs) issued by regulatory agencies like the FDA. CDMOs that don’t prioritize in-depth process development can struggle to provide the data and documentation needed for regulatory compliance, leading to delays in drug approvals and jeopardizing product launches.

Decoupling Process Development: A New Approach

To address these challenges, forward-thinking companies like APC and its clients are pioneering a new model: decoupling process development from manufacturing. This strategy involves taking full ownership of the process development phase, ensuring that every aspect of the process is developed in a phase-appropriate manner – thus ensuring it is sufficiently well-understood, optimized, and documented before it enters the manufacturing phase.

The Benefits of Decoupling Process Development

Unmatched Process Understanding & Control

When process development is decoupled from manufacturing, medicine developers can focus entirely on understanding the science behind their product. This in-depth understanding includes identifying critical process parameters, optimizing reactions, and troubleshooting potential pitfalls early in the development cycle.

APC, for example, has long championed a "science-first" approach, where deep experimentation and advanced analytical tools are used to craft robust, efficient processes that can be transferred to any manufacturing site. By owning the process, medicine developers gain full control over how their product is made, ensuring that the manufacturing process is aligned with the unique requirements of their molecule.

“Process Portability” - Flexibility Across Manufacturing Sites

A major advantage of decoupling process development is the concept of Process Portability — the ability to transfer a well-understood process across multiple manufacturing sites without compromising quality or efficiency. This flexibility is invaluable in today’s dynamic pharmaceutical landscape, where companies must adapt to supply chain disruptions, regulatory changes, or shifts in market demand.

By investing in rigorous process development upfront, companies can ensure that their processes are easily scalable and transferable, reducing the risks of tech transfer failures, batch inconsistencies, or regulatory challenges. This adaptability also provides developers with the freedom to choose the best manufacturing partner based on capacity, expertise, or geographic location, rather than being locked into a single CDMO's infrastructure. 

Accelerated Time-to-Market

In the traditional CDMO model, process development often plays catch-up to manufacturing timelines. Decoupling these functions allows medicine developers to focus on optimizing the process early, reducing the need for costly iterations and reworks during the later stages of commercialization. This streamlined approach can significantly accelerate the path to regulatory approval and market entry.

At APC, the emphasis on The Medicine Accelerator’s mission reflects this commitment to speed and efficiency. By combining scientific rigor with advanced digital tools, APC has been able to reduce the time it takes to develop and optimize processes, while still ensuring full compliance with regulatory standards. This acceleration not only benefits developers but ultimately gets life-changing treatments into the hands of patients faster.

Cost Efficiency & Risk Mitigation

Decoupling process development from manufacturing allows medicine developers to avoid the "fit-to-facility" problem, where processes are retrofitted to suit existing manufacturing equipment rather than optimized for the product itself. This flexibility reduces the risk of batch failures, inefficient scaling, or regulatory setbacks that can cost millions in lost time and resources.

Furthermore, the ability to transfer a well-understood process to multiple sites offers developers a safety net in case of disruptions. In a world where supply chain vulnerabilities, geopolitical factors, and even pandemics can derail production schedules, the ability to pivot quickly and scale production in alternative locations is a significant competitive advantage.

A Focus on Innovation & Breakthroughs

By decoupling process development, companies can foster a culture of continuous innovation. Rather than being constrained by the limitations of a CDMO's manufacturing infrastructure, developers are free to explore novel process technologies, experiment with new materials, or even design completely new approaches to production.

For APC, this focus on innovation has been key to transforming the cost and complexity of manufacturing breakthrough medicines, from small molecules through the range of large molecule biologics and ATMP’s . By combining cutting-edge chemical engineering with advanced digital tools like iAchieve, APC continues to push the boundaries of what's possible in pharmaceutical manufacturing.

 A New Era in Pharmaceutical Development

The benefits of decoupling process development from manufacturing are clear: greater control, enhanced flexibility, faster time-to-market, and reduced risks. As pharma companies navigate an increasingly complex landscape, the ability to take full ownership of process development will become a critical differentiator in delivering life-saving therapies to patients.

For APC, being a disruptor and turning the traditional CDMO model on its head represents a reimagining of how medicines are developed, manufactured, and delivered. By focusing on scientific excellence, radical collaboration, and digital innovation, APC is leading the charge in transforming CMC into a driver of pharmaceutical success, ensuring that the medicines of tomorrow are made with the precision, efficiency, and flexibility needed to meet the demands of today.